We performed this retrospective study to investigate whether the KRAS mutation status and its subtypes could predict the effect of first-line platinum-based chemotherapy in Chinese patients with non-small cell lung cancer (NSCLC). Patients received who had KRAS mutations were enrolled. Correlations ...
(adenocarcinoma vs. squamous cell carcinoma) and mutational state of the protein, C-K-RAS (KRAS) and the epidermal growth factor receptor (EGFR) gene. When considering the whole cancer genome, taking into consideration the preponderance of DNA alteration or specific mutations is the key to ...
Squamous: These tumors have enriched TP53 and KDMA mutations. Pancreatic progenitor: These tumors express genes involved in pancreatic development such as FOXA2/3, PDX1, and MNX1. Aberrantly differentiated endocrine exocrine (ADEX): These tumors display the genes (KRAS) and exocrine (NR5A2 and ...
MM-related mutations BRAF KRAS MYC NRAS TP53 Plasma cell dyscrasias AL amyloidosis MGCS MGRS MGUS Newly diagnosed multiple myeloma Plasma cell leukemia Relapsed/refractory multiple myeloma Smoldering multiple myeloma Solitary plasmacytoma Risk COVID-19 Favorable-risk High-riskBrought...
S5). Several proteome-specific modules were differentially expressed in tumors and they were involved in KRAS-driven HEME metabolism (Additional file 1: Fig. S6C), spliceosome interacting with mutational drivers in chromatic remodeling (Additional file 1: Fig. S6D), DNA single-strand break repair ...
EP: 2.Different Types of Biomarker Testing Methods Used in Patients with NSCLC EP: 3.KRASG12C Mutations and CNS Metastases in Patients with NSCLC EP: 4.Review of KRYSTAL 1b and Role of Adagrasib in Patients With Untreated CNS Metastases ...
et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 8, 822–835 (2018). Article CAS PubMed PubMed Central Google Scholar Samstein, R. M. et al. Mutations in BRCA1 and BRCA2 differentially affect the tumor microenvironment and ...
Additionally, mutually exclusive KRAS-TP53 mutations were identified in the high-risk cohort, suggesting that these gene mutations are unlikely to co-occur in the same sample (Fig. 7E). Figure 7F revealed that he low-risk cohort also exhibited mutual exclusivity and co-occurrence of gene ...
Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations. Cell Rep. Methods 1, 100084 (2021). Bear, A. S. et al. Biochemical and functional characterization of mutant KRAS epitopes validates this oncoprotein for immunological targeting. Nat. Commun. 12, 4365...
Comprehensive genetic variant analysis reveals combination of KRAS and LRP1B as a predictive biomarker of response to immunotherapy in patients with non-small cell lung cancer Ella A. Eklund Johanna Svensson Anna Rohlin Journal of Experimental & Clinical Cancer Research(2025) ...